title: The initial management of stable angina in Europe, from the Euro Heart Survey: a description of pharmacological management and revascularization strategies initiated within the first month of presentation to a cardiologist in the Euro Heart Survey of Stable Angina.
abstract: OBJECTIVE
  In order to assess adherence to guidelines and international variability in management, the Euro Heart Survey of Newly Presenting Angina prospectively studied medical therapy, percutaneous coronary intervention (PCI), and surgery in patients with new-onset stable angina in Europe.
  
  
  RESULTS
  Consecutive patients, 3779 in total, with a clinical diagnosis of stable angina by a cardiologist were enrolled. After initial assessment by a cardiologist, 78% were treated with aspirin, 48% with a statin, and 67% with a beta-blocker. ACE-inhibitors were prescribed by the cardiologist in 37% overall. Revascularization rates were low, with only 501 (13%) patients having PCI or coronary bypass surgery performed or planned. However, when restricted to patients with coronary disease documented within 4 weeks of assessment, over 50% had revascularization performed or planned. Among other factors, the national rate of angiography and availability of invasive facilities significantly predicted the likelihood of revascularization, OR 2.4 and 2.0, respectively.
  
  
  CONCLUSIONS
  This survey shows a shortfall between guidelines and practice with regard to the use of evidence-based drug therapy and evidence that revascularization rates are strongly influenced by non-clinical, in addition to clinical, factors.
authors.affiliation: Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. c.daly@rbh.nthames.nhs.uk
authors.forename: Caroline A
authors.initials: CA
authors.lastname: Daly
authors.forename: Felicity
authors.initials: F
authors.lastname: Clemens
authors.forename: Jose L Lopez
authors.initials: JL
authors.lastname: Sendon
authors.forename: Luigi
authors.initials: L
authors.lastname: Tavazzi
authors.forename: Eric
authors.initials: E
authors.lastname: Boersma
authors.forename: Nicholas
authors.initials: N
authors.lastname: Danchin
authors.forename: Francois
authors.initials: F
authors.lastname: Delahaye
authors.forename: Anselm
authors.initials: A
authors.lastname: Gitt
authors.forename: Desmond
authors.initials: D
authors.lastname: Julian
authors.forename: David
authors.initials: D
authors.lastname: Mulcahy
authors.forename: Witold
authors.initials: W
authors.lastname: Ruzyllo
authors.forename: Kristian
authors.initials: K
authors.lastname: Thygesen
authors.forename: Freek
authors.initials: F
authors.lastname: Verheugt
authors.forename: Kim M
authors.initials: KM
authors.lastname: Fox
mesh_terms: D000704:Analysis of Variance; D000787:Angina Pectoris / Q000517:prevention & control*; D015906:Angioplasty, Balloon, Coronary / Q000706:statistics & numerical data; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D003657:Decision Making; D005060:Europe; D005260:Female; D019983:Guideline Adherence; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000517:prevention & control; D009204:Myocardial Revascularization / Q000706:statistics & numerical data*; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012044:Regression Analysis
chemical_list: D002317:Cardiovascular Agents